LT3347349T - Fluorindolo dariniai kaip muskarininio m1 receptoriaus teigiami alosteriniai moduliatoriai - Google Patents
Fluorindolo dariniai kaip muskarininio m1 receptoriaus teigiami alosteriniai moduliatoriaiInfo
- Publication number
- LT3347349T LT3347349T LT16750259T LT16750259T LT3347349T LT 3347349 T LT3347349 T LT 3347349T LT 16750259 T LT16750259 T LT 16750259T LT 16750259 T LT16750259 T LT 16750259T LT 3347349 T LT3347349 T LT 3347349T
- Authority
- LT
- Lithuania
- Prior art keywords
- reciptor
- muscarary
- fluorindoline
- derivatives
- positive allosteric
- Prior art date
Links
- 230000003281 allosteric effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN4809CH2015 | 2015-09-10 | ||
| PCT/IB2016/054290 WO2017042643A1 (en) | 2015-09-10 | 2016-07-19 | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3347349T true LT3347349T (lt) | 2019-12-10 |
Family
ID=56618200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT16750259T LT3347349T (lt) | 2015-09-10 | 2016-07-19 | Fluorindolo dariniai kaip muskarininio m1 receptoriaus teigiami alosteriniai moduliatoriai |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10294217B2 (lt) |
| EP (1) | EP3347349B1 (lt) |
| JP (1) | JP6553811B2 (lt) |
| KR (1) | KR102068237B1 (lt) |
| CN (1) | CN108026073B (lt) |
| AU (1) | AU2016320645B2 (lt) |
| BR (1) | BR112018004719B1 (lt) |
| CA (1) | CA2997956C (lt) |
| CY (1) | CY1122321T1 (lt) |
| DK (1) | DK3347349T3 (lt) |
| EA (1) | EA033826B1 (lt) |
| ES (1) | ES2750868T3 (lt) |
| HR (1) | HRP20191869T1 (lt) |
| HU (1) | HUE047056T2 (lt) |
| IL (1) | IL257869A (lt) |
| LT (1) | LT3347349T (lt) |
| MA (1) | MA42769B1 (lt) |
| MD (1) | MD3347349T2 (lt) |
| ME (1) | ME03571B (lt) |
| MX (1) | MX379454B (lt) |
| NZ (1) | NZ740587A (lt) |
| PL (1) | PL3347349T3 (lt) |
| PT (1) | PT3347349T (lt) |
| RS (1) | RS59473B1 (lt) |
| SI (1) | SI3347349T1 (lt) |
| SM (1) | SMT201900608T1 (lt) |
| WO (1) | WO2017042643A1 (lt) |
| ZA (1) | ZA201801463B (lt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11234979B2 (en) * | 2017-10-18 | 2022-02-01 | Suven Life Sciences Limited | Heteroaryl compounds as muscarinic M1 receptor positive allosteric modulators |
| MA50464A (fr) * | 2017-10-27 | 2021-06-02 | Suven Life Sciences Ltd | Amides polycycliques utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1 |
| MX2022009528A (es) * | 2020-02-04 | 2022-11-14 | Mindset Pharma Inc | Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| CN115385849B (zh) * | 2022-09-14 | 2024-01-26 | 南通瑞合达医药科技有限公司 | 一种N-Boc-3-氟-4-哌啶酮提纯的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60123485A (ja) | 1983-12-08 | 1985-07-02 | Yoshitomi Pharmaceut Ind Ltd | インド−ル−3−カルボキサミド誘導体 |
| WO2001058869A2 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| JP5192389B2 (ja) | 2005-12-05 | 2013-05-08 | メルク・シャープ・エンド・ドーム・コーポレイション | キノロンm1レセプター陽性アロステリックモジュレータ |
| AU2010286683B9 (en) * | 2009-08-31 | 2014-09-04 | Merck Sharp & Dohme Llc | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators |
| US9199939B2 (en) * | 2009-12-17 | 2015-12-01 | Merck Sharp & Dohme Corp. | Quinoline amide M1 receptor positive allosteric modulators |
| EP2575454B1 (en) | 2010-05-28 | 2018-08-29 | Merck Sharp & Dohme Corp. | Naphthalene carboxamide m1 receptor positive allosteric modulators |
| TW201512197A (zh) | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
| MX2016001942A (es) * | 2013-09-27 | 2016-06-02 | Hoffmann La Roche | Derivados de indol e indazol. |
| GB201317363D0 (en) * | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| WO2015080904A1 (en) | 2013-11-27 | 2015-06-04 | Vanderbilt University | Substituted 4-benzyl-3,4-dihydro-2h-benzo[b][1,4]oxazine-2carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor m1 |
-
2016
- 2016-07-19 MA MA42769A patent/MA42769B1/fr unknown
- 2016-07-19 HR HRP20191869TT patent/HRP20191869T1/hr unknown
- 2016-07-19 SI SI201630447T patent/SI3347349T1/sl unknown
- 2016-07-19 MX MX2018002821A patent/MX379454B/es unknown
- 2016-07-19 WO PCT/IB2016/054290 patent/WO2017042643A1/en not_active Ceased
- 2016-07-19 NZ NZ740587A patent/NZ740587A/en unknown
- 2016-07-19 MD MDE20180689 patent/MD3347349T2/ro unknown
- 2016-07-19 PL PL16750259T patent/PL3347349T3/pl unknown
- 2016-07-19 KR KR1020187009938A patent/KR102068237B1/ko active Active
- 2016-07-19 US US15/758,313 patent/US10294217B2/en active Active
- 2016-07-19 SM SM20190608T patent/SMT201900608T1/it unknown
- 2016-07-19 ME MEP-2019-288A patent/ME03571B/me unknown
- 2016-07-19 BR BR112018004719-8A patent/BR112018004719B1/pt active IP Right Grant
- 2016-07-19 EP EP16750259.0A patent/EP3347349B1/en active Active
- 2016-07-19 LT LT16750259T patent/LT3347349T/lt unknown
- 2016-07-19 HU HUE16750259A patent/HUE047056T2/hu unknown
- 2016-07-19 ES ES16750259T patent/ES2750868T3/es active Active
- 2016-07-19 AU AU2016320645A patent/AU2016320645B2/en active Active
- 2016-07-19 RS RS20191328A patent/RS59473B1/sr unknown
- 2016-07-19 JP JP2018512868A patent/JP6553811B2/ja active Active
- 2016-07-19 DK DK16750259T patent/DK3347349T3/da active
- 2016-07-19 CA CA2997956A patent/CA2997956C/en active Active
- 2016-07-19 CN CN201680052764.2A patent/CN108026073B/zh active Active
- 2016-07-19 PT PT167502590T patent/PT3347349T/pt unknown
- 2016-07-19 EA EA201890684A patent/EA033826B1/ru unknown
-
2018
- 2018-03-02 ZA ZA2018/01463A patent/ZA201801463B/en unknown
- 2018-03-05 IL IL257869A patent/IL257869A/en active IP Right Grant
-
2019
- 2019-10-16 CY CY20191101086T patent/CY1122321T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3319956T3 (da) | Substituerede oxopyridinderivater | |
| DK3394033T3 (da) | Heterocykliske forbindelser som immunmodulatorer | |
| EP3337502A4 (en) | STABLE ANTI-IFNAR1 FORMULATION | |
| MA53943A (fr) | Modulateurs de ror-gamma | |
| DK3331876T3 (da) | Modulators of ror-gamma | |
| LT3204359T (lt) | Tetrahidroizochinolino dariniai | |
| DK3131902T3 (da) | Forbindelser som ROR-gamma-modulatorer | |
| DK3386954T3 (da) | Dimere kontrastmidler | |
| EP4258061C0 (en) | DEVELOPMENT CARTRIDGE | |
| HUE048321T2 (hu) | Karabazol származékok | |
| CL2015001019S1 (es) | Ampolleta | |
| LT3402792T (lt) | Chinolin-2-ono dariniai | |
| DK3322967T3 (da) | Viskositetsmålinger | |
| LT3457851T (lt) | Sobetiromo dariniai | |
| DK3231803T3 (da) | Dihydroindolizinonderivat | |
| LT3371168T (lt) | Indolin-2-ono dariniai | |
| DK3131898T3 (da) | Fluoroalkylfluorenderivativer | |
| PT3143018T (pt) | Derivados da caboxamida | |
| DK3145916T3 (da) | Imidazolderivater som formylpeptidreceptormodulatorer | |
| DK3371163T3 (da) | Pyrrolidinderivater | |
| LT3347349T (lt) | Fluorindolo dariniai kaip muskarininio m1 receptoriaus teigiami alosteriniai moduliatoriai | |
| DK3173071T4 (da) | Maropitantformulering | |
| DK4056557T3 (da) | Benzazepinderivater nyttige som medikamenter | |
| PL3137460T3 (pl) | Pochodne diheterocyklu połączonego cykloalkilem | |
| LT3097076T (lt) | Nauji cip-eikozanoidų dariniai |